Gs Fi C 29 (BV78) News

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Dyadic to Attend Industry Events in June

JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial...

Dyadic to Attend Industry and Investor Events in May

JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”...

Form EFFECT - Notice of Effectiveness

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or...

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no...

Dyadic Announces Change in Board and Management Leadership Roles

JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or...

Dyadic to Attend Industry Events in April

JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”...